Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Ammonia Solution, Strong. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 16/20 | 0.46 |
| ▸ | CA2 | P00918 | 16/20 | 0.46 |
| ▸ | CA9 | Q16790 | 15/20 | 0.46 |
| ▸ | CA12 | O43570 | 5/20 | 0.46 |
| ▸ | CA7 | P43166 | 5/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.46 |
| ▸ | CA3 | P07451 | 4/20 | 0.46 |
| ▸ | CA4 | P22748 | 4/20 | 0.46 |
| ▸ | CA6 | P23280 | 4/20 | 0.46 |
| ▸ | CA5A | P35218 | 4/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL17456492 | 0.89 | RECQL (0.70) | RECQLTSHRGLAHPGDMAPK1 | |
| Lithium Ion SCHEMBL17456412 | 0.89 | RECQL (0.70) | RECQLTSHRGLAHPGDMAPK1 | |
| Lithium Ion SCHEMBL17456418 | 0.86 | RECQL (0.65) | RECQLTSHRGLAHPGDMAPK1 | |
| Ammonia Solution, Strong SCHEMBL28293425 | 0.84 | RECQL (0.92) | RECQLTSHRGLAHPGDMAPK1 | |
| SCHEMBL1627584 | 0.83 | RECQL (0.91) | RECQLTSHRGLAHPGDMAPK1 | |
| Water SCHEMBL7534502 | 0.81 | RECQL (0.96) | RECQLTSHRGLAHPGDMAPK1 | |
| Water SCHEMBL771625 | 0.81 | RECQL (0.96) | RECQLTSHRGLAHPGDMAPK1 | |
| Water SCHEMBL11831858 | 0.81 | RECQL (0.88) | RECQLTSHRGLAHPGDMAPK1 | |
| Water SCHEMBL669056 | 0.81 | RECQL (0.96) | RECQLTSHRGLAHPGDMAPK1 | |
| Water SCHEMBL11142572 | 0.81 | RECQL (0.88) | RECQLTSHRGLAHPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2740738-B1 | PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASE, PREPARATION METHODS AND USES THEREOF | BEIJING FSWELCOME TECH DEVELOPMENT CO LTD (CN) | 2018-03-28 | — | — | EP | disclosed |
| EP-2759547-B1 | PLATINUM COMPOUND HAVING AMINO- OR ALKYLAMINO-CONTAINING SUCCINIC ACID DERIVATIVES AS LEAVING GROUP, PREPARATION METHOD THEREFOR, AND USE THEREOF | BEIJING FSWELCOME TECH DEV CO LTD (CN) | 2017-01-18 | — | — | EP | disclosed |
| US-9175024-B2 | Platinum compound having amino or alkylamino-containing succinic acid derivatives as leaving group, preparation method thereof, and use thereof | BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2015-11-03 | — | — | US | disclosed |
| US-9138421-B2 | Platinum compounds for treating cell proliferative diseases, preparation method and use thereof | BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2015-09-22 | — | — | US | disclosed |
| US-20140349985-A1 | PLATINUM COMPOUND HAVING AMINO OR ALKYLAMINO-CONTAINING SUCCINIC ACID DERIVATIVES AS LEAVING GROUP, PREPARTION METHOD THEREOF, AND USE THEREOF | BEIJING SHOWBY PHARMACEUTICAL CO., LTD. (CN) | 2014-11-27 | — | — | US | disclosed |
| EP-2759547-A1 | PLATINUM COMPOUND HAVING AMINO- OR ALKYLAMINO-CONTAINING SUCCINIC ACID DERIVATIVES AS LEAVING GROUP, PREPARATION METHOD THEREFOR, AND USE THEREOF | Beijing Fswelcome Technology Development Co., Ltd (CN) | 2014-07-30 | — | — | EP | disclosed |
| EP-2740738-A1 | PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASE, PREPARATION METHODS AND USES THEREOF | Beijing FSwelcome Technology Development Co., Ltd. (CN) | 2014-06-11 | — | — | EP | disclosed |
| US-20140142079-A1 | PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASES, PREPARATION METHOD AND USE THEREOF | BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142079-A1 | PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASES, PREPARATION METHOD AND USE THEREOF | PCNA, POLI, MKI67 | RECQL 436/4885TSHR 3335/4885GLA 2500/4885 |
| US-20140349985-A1 | PLATINUM COMPOUND HAVING AMINO OR ALKYLAMINO-CONTAINING SUCCINIC ACID DERIVATIVES AS LEAVING GROUP, PREPARTION METHOD THEREOF, AND USE THEREOF | SLC7A5, SLC43A1, SLC7A1 | RECQL 1975/4885TSHR 4192/4885GLA 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.